Clinical trials: Ocular Inflammation and Pain After Cataract Surgery
- Condition Ocular Inflammation and Pain After Cataract Surgery
- Funder type Industry (pharma, biotech, devices)
Cataract
Confirmatory Study Nepafenac 0.3%
The purpose of this study was to assess the safety and efficacy of an investigational eye drop intended for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
- Trial name
- NCT01109173
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Ophthalmic Suspension 0.3% Vehicle
- Where
- United States
- Volunteers
- 2,120 people
- Sponsor
- Alcon Research
Cataract
Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery
The objective of this clinical study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
- Trial name
- NCT01230125
- Testing
- Mapracorat, Vehicle
- Where
- United States
- Volunteers
- 311 people
- Sponsor
- Bausch & Lomb Incorporated
Post Ocular Surgical Inflammation and Pain
Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects who have undergone…
- Trial name
- NCT02034019
- Testing
- Dexamethasone, Punctum Plug
- Where
- United States
- Volunteers
- 247 people
- Sponsor
- Ocular Therapeutix, Inc.
Inflammation Eye Pain, Postoperative Cataract
A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
This was a randomized, double-masked, vehicle-controlled, Phase 3 study evaluating the efficacy and safety of OCS-01 QD compared to vehicle in the treatment of inflammation and pain following cataract surgery.
- Trial name
- OPTIMIZE-2 (NCT06128369)
- Testing
- OCS-01, Vehicle
- Where
- 24 sites in United States
- Volunteers
- 117 people
- Sponsor
- Oculis
Postoperative Ocular Inflammation, Postoperative Ocular Pain
A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery
This study is designed to evaluate the safety and efficacy of TRIESENCE® (triamcinolone acetonide injectable suspension) in patients undergoing ophthalmic procedures.
- Trial name
- NCT07832552
- Testing
- TRIESENCE (triamcinolone acetonide injectable suspension)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Harrow Inc
Ocular Inflammation and Pain
Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery
This Phase 3 study will evaluate APP13007 in comparison to the matching vehicle placebo in a randomized, parallel-group, double-masked fashion.
- Trial name
- NCT04739709
- Testing
- APP13007, 0.05%
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 378 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Cataracts Infantile
Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
Multicenter, randomized, evaluator-blinded clinical trial compared to Prednisolone acetate, 1% in the treatment of inflammation and pain after cataract surgery in pediatric population.
- Trial name
- CLOSE-3 (NCT05724446)
- Testing
- Clobetasol Propionate, Prednisolone acetate ophthalmic suspension, 1%
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Salvat
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and…
- Trial name
- NCT02736175
- Testing
- Dexamethasone
- Volunteers
- 438 people
- Sponsor
- Ocular Therapeutix, Inc.
Inflammation, Pain
Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate ophthalmic gel
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT01996839
- Testing
- Loteprednol Etabonate Gel (BID), Loteprednol Etabonate Gel (TID), Vehicle (BID)
- Where
- United States
- Volunteers
- 514 people
- Sponsor
- Bausch & Lomb Incorporated
Cataract, Pain
LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Loteprednol Etabonate Ophthalmic Gel, (BID and TID) versus Vehicle Group for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.
- Conditions
- Cataract, Pain, Ocular Inflammation
- Trial name
- NCT02786901
- Testing
- Loteprednol Etabonate Ophthalmic Gel dosed TID, Loteprednol Etabonate Ophthalmic Gel dosed BID, Vehicle Gel
- Where
- 6 sites in United States
- Volunteers
- 600 people
- Sponsor
- Bausch & Lomb Incorporated
Cataract
A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery
This is a safety and efficacy study of a Dexamethasone Drug Delivery System for anterior segment inflammation and pain following cataract extraction with lens implantation.
- Trial name
- NCT01605942
- Testing
- Dexamethasone Drug Delivery System
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Allergan
Post-surgical Ocular Inflammation, Post-surgical Ocular Pain
Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects
SURF-201 is being studied for the treatment of eye inflammation and pain in people who are undergoing cataract surgery. SURF-201 is an investigational drug (which means the study drug is currently being tested) in the form of a…
- Trial name
- NCT04324359
- Testing
- SURF-201
- Where
- 10 sites in United States
- Volunteers
- 91 people
- Sponsor
- Surface Ophthalmics, Inc.
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and…
- Trial name
- NCT02089113
- Testing
- Dexamethasone
- Volunteers
- 241 people
- Sponsor
- Ocular Therapeutix, Inc.
Cataract, Inflammation
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
The objective of this clinical study is to compare the safety and efficacy of mapracorat ophthalmic suspension, 3% with its vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
- Conditions
- Cataract, Inflammation, Surgery
- Trial name
- NCT01591161
- Testing
- Mapracorat
- Where
- United States
- Volunteers
- 369 people
- Sponsor
- Bausch & Lomb Incorporated
Ocular Inflammation and Pain After Cataract Surgery
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
This is a Phase 2a, 2-part study (designated Parts A and B) that will evaluate APP13007 dose strength and dosing frequency in a randomized double-masked fashion for comparison to the respective matching vehicle placebo.
- Trial name
- NCT04089735
- Testing
- APP13007, 0.05%, APP13007, 0.1%
- Where
- 9 sites in United States
- Volunteers
- 165 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Inflammation, Pain
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain
The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT02508337
- Testing
- XG-102
- Where
- United States
- Volunteers
- 309 people
- Sponsor
- Xigen SA
Cataract, Inflammation
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
The objective of this clinical study is to compare the safety and efficacy of mapracorat ophthalmic suspension, 3% with its vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
- Conditions
- Cataract, Inflammation, Surgery
- Trial name
- NCT01591655
- Testing
- Mapracorat, Vehicle
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Bausch & Lomb Incorporated
Inflammation Corneal, Pain, Postoperative
OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
The DX-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle in the treatment of inflammation and pain following cataract…
- Trial name
- SKYGGN (NCT04130802)
- Testing
- OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL
- Where
- 4 sites in United States
- Volunteers
- 153 people
- Sponsor
- Oculis
Corneal Endothelial Cell Loss, Ocular Pain
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
This study assesses the efficacy and safety of two concentrations of omaveloxolone (RTA 408) ophthalmic suspension for the prevention of corneal endothelial cell loss following cataract surgery.
- Conditions
- Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery
- Trial name
- NCT02128113
- Testing
- Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1%
- Where
- 15 sites in United States
- Volunteers
- 307 people
- Sponsor
- Biogen
Cataract
A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%
This is a post-approval, open-label, randomized, self-controlled prospective clinical study to evaluate the safety and ocular efficacy of Dexycu in controlling postoperative ocular pain and inflammation associated with cataract…
- Trial name
- NCT04273282
- Testing
- Dexycu intracameral dexamethasone, Prednisolone Acetate
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Research Insight LLC